finanzen.net

Prometic Life Sciences - die bessere Genta?

Seite 2 von 2
neuester Beitrag: 16.02.11 10:19
eröffnet am: 10.03.10 13:38 von: oki-wan Anzahl Beiträge: 43
neuester Beitrag: 16.02.11 10:19 von: Oki-Wan 2.0 Leser gesamt: 9228
davon Heute: 3
bewertet mit 5 Sternen

Seite: 1 |
 

04.12.10 02:11

125 Postings, 3756 Tage TheOracleXEin kleiner Happen aus den Information of interest

Therapeutics / PBI-1402

http://www.prometic.com/en/prometic/information.php

Posted on October 15, 2010

ProMetic would like to bring to your attention a recently published article titled "FDA Considers Restricting Amgen Anemia Drugs".

This article states that the Food and Drug Administration is considering new restrictions on widely used anemia drugs that appear to double the risk of stroke in patients with kidney disease and in addition the FDA review states that the ?Treatment did not eliminate the risk of requiring (red blood cell) transfusions".

Given that ProMetic?s PBI-1402 compound does not elevate hemoglobin or red blood cells to potentially dangerous levels (no overshoot), it provides unique positioning strategies for this medical condition that the Company is actively pursuing.  

04.12.10 02:24
1

125 Postings, 3756 Tage TheOracleX@ alle Prometic - Freunde

Die Faktenlage von Prometic hat sich seit Anfang September verändert:
- neue Partnerschaft mit Allist
- quartalsbericht ok, wieder einige verbesserungen
- fda zieht restriktionen bezüglich anämie-medikamenten in betracht, die in konkurrenz zu PBI-1402 stehen = bessere bzw. super chancen für PBI-1402, weil andere funtionsweise!
- nur der aktienkurs scheint davon noch nicht so richtig etwas mitbekommen zu haben...

wenn ab nächsten jahr die italiener ihre licensing fees an prometic abstottern, gibt es wahrscheinlich den ersten knall richtung decke (was natürlich auch wunschdenken widerspiegelt). dennoch gibt es sonst keine bad news, die den niedrigen kurs rechtfertigen. prometic stellt sich für die zukunft auf! vor einigen jahren war es sumitomo für japan, jetzt kommt allist für china hinzu; m.e. die kaufchance. und jetzt drücken wir mal hier schön die daumen...

TheOracleX

meine subjektive meinung.keine kaufempfehlung.  

14.12.10 18:20
1

125 Postings, 3756 Tage TheOracleX@all

Noch mal zu Erinnerung:
Der Kurs in Deutschland sagt übrhaupt nichts aus (außer Berlin vielleicht).
Guckt euch die 12 CAD-Cent an in Toronto!!! Da wird die Musik gemacht.
Und ja, mea culpa, ich habe es immer noch nicht geschafft eine neue Prognose zu PLI zu machen. Aber ich arbeite dran ;-).... Und jetzt steig endlich an, du Sau!
TheOracleX  

29.01.11 01:10
1

617 Postings, 3743 Tage Oki-Wan 2.0@all

HEY ORACLE! ICH WARTE IMMER NOCH AUF DIE "NEUE" PROGNOSE...
Beste Grüße, Oki-Wan 2.0  

29.01.11 13:52
1

125 Postings, 3756 Tage TheOracleX@oki-wan

du, ich bin gar nicht in town und hab echt zufällig mal reingeschaut freut mich dass du noch interesse an prometic hast werde hier demnächst was reinstellen aber dauert noch familie und job nimmt mich voll in Anspruch bis bald oracle  

30.01.11 13:55

125 Postings, 3756 Tage TheOracleX@all

Hola companeros.
Im nachfolgenden nun ein Link zur letzten Präsentation von PLI:
http://www.prometic.com/docs/events/...tic_Jan_12_BioTech_Shocase.pdf

Dem kann und will ich eigentlich nichts mehr hinzufügen, da alles wichtige bereits gesagt wurde. Ich glaube weiterhin an Prometic und bescheinige ihr nach wie vor großes Potential.
Good luck allen investierten und bis bald,
TheOracleX

Wie immer keine Kauf- oder Verkaufsempfehlung.  

31.01.11 19:39
1

617 Postings, 3743 Tage Oki-Wan 2.0@all

Hiermit stelle ich euch den Link zur aktuellsten Pressemitteilung rein:
http://www.prometic.com/en/news-events/...change-terms-630.php?y=2011

Vor dem Hintergrund der jüngsten Entwicklungen (siehe Posting oben von Oracle) gehe ich ab spätestens Ende 2011 von schwarzen Zahlen aus. Dass die Anteilseigner auf die Rückzahlung ihrer gesicherten Anleihen bis Juli 2012 verzichten, damit Prometic sich voll auf die Fortentwicklung ihrer Produkte konzentrieren kann, sehe ich wie in der Mitteilung verfasst als Vertrauen in die Firma. Gleichzeitig wird durch die Verschiebung der Einfluss (gemessen an den Anteilen) von Allist Pharmac. begrenzt.
Zur Erinnerung:
Ausserdem werden dieses Jahr soweit ich weiß erste Lizenzzahlungen von Kedrion für Mimetic-Ligand-Produkte fällig, überdies noch andere Milestone-Payments. Aber der Knüller ist folgende Geschichte:
Dieses Jahr wird von der britischen Regierung endgültig ein Urteil erwartet, ob landesweit Prionenfilter bei Blutentnahmen bzw. Bluttransfusionen verwendet werden müssen. Irland und Macao haben bekanntlich damit angefangen, sollte GB nachziehen wird in Zukunft die Welle auch auf das Festland schwappen. Gerade Erkrankungen wie Creutzfeld-Jakob oder Alzheimer können dadurch ziemlich wirksam eingedämmt werden.

Hoffen wir also das Beste für unsere kleine feine Perle!

Beste Grüße,
Oki-Wan 2.0  

01.02.11 18:10

617 Postings, 3743 Tage Oki-Wan 2.0@all "dringend"

Kann mir einer mal erklären, warum Prometic nicht an der TMX gehandelt wird? Scheint jedenfalls kein Feiertag zu sein, da andere Werte munter über den Tisch gehen.
Danke im voraus für eure Antworten.
Oki-Wan 2.0  

01.02.11 22:03
1

617 Postings, 3743 Tage Oki-Wan 2.0hat sich erledigt...

Die Börse hat weder zu noch ist Prometic ausgesetzt. Es waren lediglich wie bei Ariva um 8 einige Baustellen, die zu Verzögerungen geführt haben.
Mit besten Grüßen,
Oki-Wan 2.0  

02.02.11 21:41

125 Postings, 3756 Tage TheOracleXOkiwan

Dein letztes posting trifft den Nagel auf den Kopf. 2011 wird allem Anschein nach ein bombiges Jahr für Prometic.
Ich hoffe nur dass die Securities holder nicht auf ihr Geld verzichten, weil sonst Prometic pleite ist.
OracleX  

02.02.11 21:47

125 Postings, 3756 Tage TheOracleXmeinte #32 !

07.02.11 20:14
1

617 Postings, 3743 Tage Oki-Wan 2.0PLI wird uns glücklich machen...

Liebe Mitleser,

folgende Nachricht wurde heute von Prometic herausgegeben und sollte manchem als Anregung dienen, sich mehr über Prometic zu informieren. Mir schwant da was...

 

ProMetic achieves pivotal milestone for its plasma-derived therapeutics business

  • Company secures an established state-of-the-art manufacturing facility on very favourable terms
  • Facility to scale-up ProMetic's proven manufacturing technology for plasma-derived therapeutics ("PPPSTM") with a targeted capacity of 150,000 liters of plasma annually
  • New subsidiary "NewCo" created to undertake product manufacturing with targeted start-up by the end of 2011
  • NewCo to be funded by third party investors, stakeholders and government grants
  • Initial equity investment of $2.5 M CDN in NewCo has been committed; of which a first tranche of $750,000 CDN has been received

MONTREAL, QUEBEC, CANADA - February 7, 2011 - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic")  announced today that the Company has achieved a pivotal milestone for  the in-house manufacturing of plasma-derived proteins at commercial  scale thereby expanding its reach into the lucrative plasma-derived  therapeutics industry.

ProMetic, via its new subsidiary, NewCo, has entered into a long-term lease on very favorable conditions with Quebec's Institut national de la recherche scientifique ("INRS") for an existing state-of-the-art facility.

NewCo  will undertake the development and manufacturing of high-value  plasma-derived therapeutic biosimilars for ProMetic's current and future  clients.  This facility, located in Laval's biotech cluster, will have a  targeted processing capacity of 150,000 liters which would supply  products with a market value exceeding $100,000,000 CDN per annum.

NewCo  will be funded via third-party investments and is anticipated NewCo  will rapidly become self-sustaining through end product services and  sales to ProMetic's existing clients.  An initial $750,000 CDN  investment has been received as part of a $2,500,000 CDN commitment.

This  new business venture has also received pledges for additional funding  from various institutions and key stakeholders involved in ProMetic's  protein technologies activities which could amount to additional  financial contributions of $3,500,000 CDN.

"This is a key  development for ProMetic as it enables the Company to benefit, at  commercial scale, from the competitive advantage provided by our proven  Plasma Protein Purification System ("PPPSTM") as well as our  prion capture technologies. Our clients will have access to ProMetic's  in-house production of plasma-derived products, in addition to  technology transfer and skills training services," said Mr. Pierre  Laurin, ProMetic's President and Chief Executive Officer.

Mr.  Bruce Pritchard, ProMetic's Chief Financial Officer stated: "We are very  pleased to have accessed such a high quality facility on such very  favorable terms, as well as having attracted capital to catalyze this  exciting venture. The manufacturing plant will supply plasma-derived  therapeutic products to our existing and future clients which should  generate significant revenue". Mr. Pritchard added: "The plant is  expected to start up operations by the end of 2011, provide cGMP  products to be used by clients in early 2012, and reach full operating  capacity by 2014".

ProMetic will further reduce its overhead cost  by relocating its headquarters at this new facility, at the end of  March, 2011.  This also allows ProMetic to concentrate its core  activities near its existing Therapeutic division's research and  development site.

Conference Call

ProMetic  will be holding a conference call / webcast on Tuesday, February 8,  2011, at 14:00 (EDT) to discuss details regarding this announcement.

The  numbers to access the conference call are (416) 981-9000  (international) and 1 (800) 925-4216 (North America toll free). A live  audio webcast of the conference call will be available through  ProMetic's website at http://www.prometic.com/en/news-events/events.php.

An  audio replay of the call will be available for a period of seven days  as of Tuesday, February 8, 2011, at 17:00 (EDT).  The numbers to access  the audio replay are (416) 626-4100 and 1 (800) 558-5253 using access  code 21510428.  The replay of the web cast may be downloaded directly  from ProMetic's web site.    
 

About the Plasma Protein Purification System   
The Plasma Protein Purification System ("PPPSTM")  allows for the targeting and removal of multiple high-value proteins  from a single plasma sample at unprecedented activity levels using  ProMetic's Mimetic LigandTM adsorbent technology.  This  system also provides for the recovery of new biotherapeutics as they are  discovered and identified. The effect of this process is to reduce the  significant losses incurred when using the more conventional Cohn  precipitation process

About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. (http://www.prometic.com/)  is a biopharmaceutical company specialized in the research,  development, manufacture and marketing of a variety of commercial  applications derived from its proprietary Mimetic LigandTM  technology. This technology is used in large-scale purification of  biologics and the elimination of pathogens. ProMetic is also active in  therapeutic drug development with the mission to bring to market  effective, innovative, lower cost, less toxic products for the treatment  of hematology and cancer. Its drug discovery platform is focused on  replacing complex, expensive proteins with synthetic "drug-like" protein  mimetics. Headquartered in Montréal (Canada), ProMetic has R&D  facilities in the UK, the U.S. and Canada, manufacturing facilities in  the UK and business development activities in the U.S., Europe, Asia and  in the Middle-East.

Forward Looking Statements        
This  press release contains forward-looking statements about ProMetic's  objectives, strategies and businesses that involve risks and  uncertainties. These statements are "forward-looking" because they are  based on our current expectations about the markets we operate in and on  various estimates and assumptions. Actual events or results may differ  materially from those anticipated in these forward-looking statements if  known or unknown risks affect our business, or if our estimates or  assumptions turn out to be inaccurate. Such risks and assumptions  include, but are not limited to, ProMetic's ability to develop,  manufacture, and successfully commercialize value-added pharmaceutical  products, the availability of funds and resources to pursue R&D  projects, the successful and timely completion of clinical studies, the  ability of ProMetic to take advantage of business opportunities in the  pharmaceutical industry, uncertainties related to the regulatory process  and general changes in economic conditions. You will find a more  detailed assessment of the risks that could cause actual events or  results to materially differ from our current expectations on page 24 of  ProMetic's Annual Information Form for the year ended December 31,  2009, under the heading "Risk Factors".  As a result, we cannot  guarantee that any forward-looking statement will materialize. We assume  no obligation to update any forward-looking statement even if new  information becomes available, as a result of future events or for any  other reason, unless required by applicable securities laws and  regulations.  All amounts are in Canadian dollars unless stated  otherwise.

###

For further information please contact:                                                            

Pierre Laurin  
President and CEO    
ProMetic Life Sciences Inc.  
p.laurin@prometic.com         
+1.514.341.2115        
 

Anne Leduc
Manager, Investor Relations                          
   and Communications                                  
ProMetic Life Sciences Inc.                          
a.leduc@prometic.com                                 
+1.514.341.2115

 

Keine Kauf-/Verkaufsempfehlung.

 

Beste Grüße,

Oki-Wan 2.0

 

09.02.11 11:18
1

617 Postings, 3743 Tage Oki-Wan 2.0Und wieder neue Sachen von PLI bzw. der Tochter...

Also mir scheint immer mehr, dass ein technischer Angriff im Gange ist. Wie sagt man so schön in der Fachsprache: mit einer bestimmten Strategie einen bestimmten Markt penetrieren.

Jedenfalls ähnelt das Erscheinungsbild immer mehr dem eines zukünftigen multinationalen Konzerns. Dazu sei angemerkt, dass Prometic Biosciences eine 100%ige Tochter von PLI ist und deren Produkte in Europa verkauft und demnächst auch in Asien anbieten will (Macao läuft schon).

Allen Investierten ein Toi Toi Toi und Daumen hoch...

Beste Grüße, Oki-Wan 2.0

 

           
                           
header
News
Solutions Events Resources

Welcome to the BioPurification Quarterly™.  We  designed this newsletter for our customers in order to keep you  informed on the latest developments within ProMetic BioSciences Ltd  (PBL) and the industry we serve.

Inside  this issue of BioPurification Quarterly™ we explain how PBL can custom  design an affinity chromatography adsorbent to suit your bio-processing  needs and describe the application of in silico techniques to develop novel ligands for affinity chromatography. We would also like to welcome our new EMEA and Asian Sales Manager - Mr. Steve Profit.

Dr.  Dev continues to offer his technical insight by discussing the  differences between PBL's proprietary base matrices - PuraBead® 6XL and PuraBead® 6HF and we provide an overview of upcoming events for 2011.

Thanks again for your support and we hope you enjoy this edition of the newsletter.

news1news
Custom Designed Affinity Chromatography Adsorbents
 
Our on-line shop  has a number of off-the-shelf products to help in numerous  bio-processing applications. This enables you to choose the best option  quickly and place orders securely online.

However, if you have a  specific requirement for a bioseparation adsorbent not listed in our  on-line catalogue PBL's technical team can help you identify a product  which meets your specific process performance specifications. PBL has  over 20 years experience in either optimizing existing products or  designing a new custom adsorbent/resin specifically for your specific target protein.

Our  in-house scientific and technical teams are world leading experts in  the development and synthesis of affinity chromatography adsorbents and  resins. Our processes are fully scalable and can meet all challenges,  taking small scale adsorbents/resins (<25 mL) up to fully validated,  regulated and supported products (>250 L). Our products are  manufactured to an ISO 9001 accredited standard.

Below illustrates some of the different options available:    
  • Numerous adsorbent base matrices (e.g. PuraBead® 6XL, PuraBead® 6HF) for ligand attachment.
  • Adsorbent slurry available for packing in either axial or radial flow columns.
  • Pre-packed chromatography columns or single-use column applications.
  • Optimisation of any of our current off-the-shelf products for  general and specific bio-processing needs (e.g. varying adsorbent base  matrix, ligand density, spacer arm chemistry).
  • A variety of custom ligand discovery programs are available from ~4  weeks (QuickScreen) to ~17 weeks (Full Discovery Project - Stage 1) for  lead candidate identification, varying in complexity depending on your  target protein requirements.
  • A full downstream processing development package to help optimise your purification needs.
So please feel free to contact us via sales@prometicbiosciences.com  if you have any requests regarding adsorbents or resins not mentioned  in our on-line shop or if you have a requirement for something slightly  different based on our current products.
 

Back to Top
- - - - - - - - -  - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  - - - - - - - - - - - - - - - - -
 
Application of in silico techniques to develop novels ligands for affinity chromatography
 
Early stage application of affinity chromatography in  downstream processing is acknowledged as a desirable objective with the  potential to increase yields and reduce the overall cost of goods. While  protein engineering technologies are producing increasingly diverse  therapeutic proteins - whole molecules, fragments, fusion proteins -  advances in bioprocess development are enabling their production at  industrial scale. Concomitant with these developments is an increase in  the demand for sufficiently robust synthetic affinity ligands with  appropriate protein binding selectivites as primary capture affinity  adsorbents.

In the absence of suitable existing ligands, the  development of completely new ligands has analogies with the development  of novel drug compounds and the computational techniques used in the  search for novel drug compounds have been adapted and used by ProMetic  to inform a number of stages in the affinity ligand design process, and  to gain an understanding of both the target protein and adsorbent  interactions.

PBL has extensive knowledge of in silico modeling  techniques, successfully applying its bioinformatics modeling suite to  identify lead candidate adsorbents in a variety of projects. PBL  provides customers with a range of services, from virtual screening, to  the application of in silico techniques within a custom ligand discovery  program:
  • Screening of virtual ligand libraries. 
  • Diverse or focused ligand selection from virtual 'chemical space'  (Chemical Combinatorial Library CCL® ~100,000 triazine based ligands).
  • Evaluating potential binding sites using structural/functional  importance and blind docking 'roaming' of ligands to target protein  (using crystallographic information).
  • Screening designed combinatorial libraries to further explore surrounding chemical space of lead screening hits.
  • Investigating the effects of support, spacer arm and surface chemistry on binding interactions by molecular dynamic modeling.

Click here to learn more


Back to Top
- - - - - - - - -  - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  - - - - - - - - - - - - - - - - -
 
EMEA and Asia Sales Manager
 
Mr. Steve Profit
EMEA and Asian Sales Manager
Mr. Steve Profit has recently joined ProMetic as the  EMEA and Asian sales & marketing manager. Steve has over 20 years  experience in sales and marketing having previously worked in senior  European and global positions for Sigma Aldrich and Millipore. Mr.  Profit holds a M.Sc. Biomolecular Technology and a B.Sc. in Applied  Biology.

If you would like to contact Steve with regards to any of our products or services please use the details below:

Tel:             +44 (0)1223 433800

Mobile:       +44 (0)7831 848644

Email:         sprofit@prometicbiosciences.com


Back to Top
solutionssolutions
Ask Dr. Dev - What is the Difference?

Researcher and Chromatography Column
Dr. Dev Baines, PBL Technical Director
Question:

Dear Dev-  Can you please provide me  information on the base matrix used for ProMetic BioSciences Ltd  chromatography adsorbents. What is the difference between PuraBead® 6XL  and PuraBead® 6HF?

Answer-  PuraBead® is a 6% agarose bead  manufactured by a novel method which does not use any organic solvents  in the beading process. This provides uniform near mono-disperse beads  with mean bead diameter from 90 to 100 microns.

After beading the matrix is cross-linked to provide material for derivatisation with affinity ligands.

Two  different types of cross-linking chemistry are used; one to provide  PuraBead® 6XL, and one to provide PuraBead® 6HF. The key difference  between the cross-linking chemistries is the much higher flow rate  provided by the HF cross-linking chemistry. The XL cross-linking  chemistry provides very low non-specific binding and enables higher  ligand densities.

Both types of PuraBead® are used to make Mimetic Blue® SA HL adsorbents including the standard Mimetic Blue® SA HL P6XL  product which is widely used for purification of albumin and  albumin-fusion proteins and the new Mimetic Blue® SA HL P6HF which  provides the same selectivity and capacity with exceptional flow  properties.

The properties of the two cross-linked base matrices are summarized below: 
PuraBead info and Curve
Do you have a question for Dr. Dev? Click here to submit your question to Dr. Dev.

Back to Top
eventsevents
Upcoming Events

PBL Trade Show BoothIBC Biopharmaceutical Development & Production Week
Date: March 14, 2011
Location: Hyatt Regency Bellevue, WA
For more information or to register click here
Save 25% off this conference compliments of PBL!
Use Priority Code: BDPSPX29 when registering to receive your discount

PRION 2011: New World
Date: May 16-19, 2011
Location: Fairmont Queen Elizabeth Hotel
Montreal, Quebec
For more information click here

BioProcess International Europe Conference and Exhibition
Date: April 6-7, 2011
Location: Nice Acropolis Des Congres, France
For more information click here
 

Back to Top
resourcesresources
Corporate Site Links Applications & Products  
About Us
Applications & Products
Shop
Services
Literature & Downloads
Events
Antibody & AntibodyFragments
Albumin & AlbuminFusion Proteins
Glycoprotein Separation
Plasma Proteins
Prion Removal
Other Proteins
Contaminant Reduction
Protease Removal
Endotoxin Removal
Glycoprotein Removal
Pathogen Reduction
Nucleic Acid Purification

Back to Top
- - - - - - - - -  - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  - - - - - - - - - - - - - - - - -
ProMetic BioSciences Ltd is a private company limited by shares, incorporated in the Isle of Man with registered number 034251C. The company is also registered as a foreign company at Companies House in the UK, with registration number FC027128. ProMetic BioSciences UK is the branch name of ProMetic BioSciences Ltd, and is registered as a Branch in England & Wales with registration number BR009067.  The registered office of ProMetic BioSciences UK and ProMetic BioSciences Ltd is Freeport, Ballasalla, Isle of Man, IM9 2AP, British Isles.  The liability of the members of ProMetic BioSciences Ltd is limited.

Copyright © 2010 ProMetic BioSciences Ltd All rights reserved.
 
 
 
       
This email was sent to lacino@gmx.net by newsletter@prometicbiosciences.com |  
ProMetic BioSciences Ltd. | 211 Cambridge Science Park | Cambridge | CB4 0WA | United Kingdom

 

 

10.02.11 00:32

125 Postings, 3756 Tage TheOracleXOkiWan

Dein Wort in Gottes Ohren  

11.02.11 11:24
2

617 Postings, 3743 Tage Oki-Wan 2.0@all

Sehr geehrte Damen und Herren,

hier der Link zu Proemtic's letzter Präsentation zu der neuen Fertigungsanlage:

http://www.prometic.com/docs/events/...ic_Laval_Facility_EN_FINAL.pdf

Viel Spaß beim durchschauen.

Beste Grüße,
Oki-Wan 2.0  

14.02.11 18:46

125 Postings, 3756 Tage TheOracleXmaaaaaaaaaaaaaaan !

wieso klebt der kurs bei 0,15pipapo wenn es so gute News gibt????
prometic macht mich total fertig. muss erst mal bu....
tschüss  

16.02.11 00:22
1

17 Postings, 3460 Tage Zohan???

Verstehe ich auch nicht!
Warum gibt es kein Volumen???  

16.02.11 10:19
1

617 Postings, 3743 Tage Oki-Wan 2.0@Zohna

Ich befürchte, weil die Aktie hier weitgehend unbekannt ist.
Übrigens werde ich gleich einen neuen Thread zu Prometic eröffnen.
Ich finde, der alte Name "... - die bessere Genta" ist nun wirklich irreführend!

Beste Grüße,
Oki-Wan 2.0  

Seite: 1 |
 
   Antwort einfügen - nach oben

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
BioNTech SE (spons. ADRs)A2PSR2
Apple Inc.865985
Plug Power Inc.A1JA81
NEL ASAA0B733
Deutsche Bank AG514000
Daimler AG710000
Amazon906866
Ballard Power Inc.A0RENB
Wirecard AG747206
TeslaA1CX3T
BayerBAY001
Deutsche Telekom AG555750
Siemens AG723610
Lufthansa AG823212
NikolaA2P4A9